HPR18 What Is the Impact of Including Outcomes-Based Agreements on the Cost-Effectiveness of Cell and Gene Therapies? A Case Example of Zynteglo for Transfusion-Dependent Beta Thalassemia

Autor:	Richardson, M 1, Beaudoin, F 2, Rind, D.M. 1, Synnott, P 3, Herce-Hagiwara, B 1, Ollendorf, D 1
Zdroj:	In Value in Health June 2024 27(6) Supplement:S198-S198
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect